Display search results for ** instead (7 products)
03 Oct 2014  |  Global
This issue of Vital Signs, released on October 3, 2014, discusses Merck KGaAs acquisition of Sigma-Aldrich, highlights from the 2014 AACC Meeting, Abbotts CE Mark for FreeStyle® Libre, laboratory developed test (LDT) regulations, and the sale of Fortis Healthcares Singapore subsidiary, RadLink-Asia Pte Ltd, and its arm, RadLink Singapore.
03 Sep 2014  |  Global
This issue of Vital Signs, released on September 3, 2014, discusses Thermo Fisher Scientifics divestment of laboratory equipment company Cole-Parmer to GTCR, the increasing use of large animal biotechnology in human health applications, the collaboration of Life Technologies and RainTree Oncology Services, the agreement between Ventana and Quintile...
04 Aug 2014  |  Global
This issue of Vital Signs, released on August 5, 2014, discusses the Senators plead to the FDA for the quick action regarding draft guidance on laboratory developed tests (LDTs), Synthetic Biologys Series A funding round, Roches investment in Stratos Genomics, and Indias cap on drug prices.
USD 375.00 save 25 %
11 Jul 2014  |  Global
Insights into the innovative steps taken by CROs and pharmaceutical companies in the race for excellence and low-cost trials
This issue of Vital Signs, released on July 11, 2014, discusses game changing strategies in clinical research, including virtual clinical research organization (CRO) and the integrated business model.
01 Jul 2014  |  Global
This issue of Vital Signs, released on July 1, 2014, discusses the FDA approval of Biogens Eloctate, Qiagens acquisition of Primera Dx, Roches acquisition of Genia Technologies, Cues at-home connected lab test, and the Credihealth Teen Clinic.
02 Jun 2014  |  Global
This issue of Vital Signs, released on June 2, 2014, discusses the latest strategy surrounding mega deals in the pharma/biotech industry, Eurofins agreement to acquire ViroCor-IBT Laboratories, Qiagens acquisition of BIOBASE, and the FDAs latest announcement on regulatory requirements for biosimilars.
30 Apr 2014  |  Global
This issue of Vital Signs, released on May 1, 2014, discusses the mega deals brewing in the pharma/biotech industry, Pfizer Incs Xalkori for non-small cell lung cancer, Novartis halt on RNAi development efforts, the high-ranked Malaysian healthcare system, Roches acquisition of IQuums Liat Analyzer, and Bio-Rads acquisition of GnuBio.